Skip to main content
Journal cover image

International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.

Publication ,  Journal Article
Dacic, S; Travis, W; Redman, M; Saqi, A; Cooper, WA; Borczuk, A; Chung, J-H; Glass, C; Lopez, JM; Roden, AC; Sholl, L; Weissferdt, A; Zhu, H ...
Published in: J Thorac Oncol
October 2023

INTRODUCTION: Pathologic response has been proposed as an early clinical trial end point of survival after neoadjuvant treatment in clinical trials of NSCLC. The International Association for the Study of Lung Cancer (IASLC) published recommendations for pathologic evaluation of resected lung cancers after neoadjuvant therapy. The aim of this study was to assess pathologic response interobserver reproducibility using IASLC criteria. METHODS: An international panel of 11 pulmonary pathologists reviewed hematoxylin and eosin-stained slides from the lung tumors of resected NSCLC from 84 patients who received neoadjuvant immune checkpoint inhibitors in six clinical trials. Pathologic response was assessed for percent viable tumor, necrosis, and stroma. For each slide, tumor bed area was measured microscopically, and pre-embedded formulas calculated unweighted and weighted major pathologic response (MPR) averages to reflect variable tumor bed proportion. RESULTS: Unanimous agreement among pathologists for MPR was observed in 68 patients (81%), and inter-rater agreement (IRA) was 0.84 (95% confidence interval [CI]: 0.76-0.92) and 0.86 (95% CI: 0.79-0.93) for unweighted and weighted averages, respectively. Overall, unweighted and weighted methods did not reveal significant differences in the classification of MPR. The highest concordance by both methods was observed for cases with more than 95% viable tumor (IRA = 0.98, 95% CI: 0.96-1) and 0% viable tumor (IRA = 0.94, 95% CI: 0.89-0.98). The most common reasons for discrepancies included interpretations of tumor bed, presence of prominent stromal inflammation, distinction between reactive and neoplastic pneumocytes, and assessment of invasive mucinous adenocarcinoma. CONCLUSIONS: Our study revealed excellent reliability in cases with no residual viable tumor and good reliability for MPR with the IASLC recommended less than or equal to 10% cutoff for viable tumor after neoadjuvant therapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Thorac Oncol

DOI

EISSN

1556-1380

Publication Date

October 2023

Volume

18

Issue

10

Start / End Page

1290 / 1302

Location

United States

Related Subject Headings

  • Reproducibility of Results
  • Oncology & Carcinogenesis
  • Neoadjuvant Therapy
  • Lung Neoplasms
  • Lung
  • Humans
  • Carcinoma, Non-Small-Cell Lung
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Dacic, S., Travis, W., Redman, M., Saqi, A., Cooper, W. A., Borczuk, A., … IASLC Pathology Committee, . (2023). International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy. J Thorac Oncol, 18(10), 1290–1302. https://doi.org/10.1016/j.jtho.2023.07.017
Dacic, Sanja, William Travis, Mary Redman, Anjali Saqi, Wendy A. Cooper, Alain Borczuk, Jin-Haeng Chung, et al. “International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.J Thorac Oncol 18, no. 10 (October 2023): 1290–1302. https://doi.org/10.1016/j.jtho.2023.07.017.
Dacic, Sanja, et al. “International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.J Thorac Oncol, vol. 18, no. 10, Oct. 2023, pp. 1290–302. Pubmed, doi:10.1016/j.jtho.2023.07.017.
Dacic S, Travis W, Redman M, Saqi A, Cooper WA, Borczuk A, Chung J-H, Glass C, Lopez JM, Roden AC, Sholl L, Weissferdt A, Posadas J, Walker A, Zhu H, Wijeratne MT, Connolly C, Wynes M, Bota-Rabassedas N, Sanchez-Espiridion B, Lee JJ, Berezowska S, Chou T-Y, Kerr K, Nicholson A, Poleri C, Schalper KA, Tsao M-S, Carbone DP, Ready N, Cascone T, Heymach J, Sepesi B, Shu C, Rizvi N, Sonett J, Altorki N, Provencio M, Bunn PA, Kris MG, Belani CP, Kelly K, Wistuba I, IASLC Pathology Committee. International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy. J Thorac Oncol. 2023 Oct;18(10):1290–1302.
Journal cover image

Published In

J Thorac Oncol

DOI

EISSN

1556-1380

Publication Date

October 2023

Volume

18

Issue

10

Start / End Page

1290 / 1302

Location

United States

Related Subject Headings

  • Reproducibility of Results
  • Oncology & Carcinogenesis
  • Neoadjuvant Therapy
  • Lung Neoplasms
  • Lung
  • Humans
  • Carcinoma, Non-Small-Cell Lung
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis